Targeting a specific pathway to treat post-traumatic osteoarthritis
Sustained Biomaterial-mediated Inhibition of R-spondin 2 to Target Pathological Wnt Signaling in Post-Traumatic Osteoarthritis
This work explores a new way to deliver medicine directly into joints to help people with post-traumatic osteoarthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11128508 on NIH RePORTER |
What this research studies
We are looking into how a specific signal, called Wnt/β-Catenin, contributes to joint damage in post-traumatic osteoarthritis. Our goal is to understand the role of a protein called R-spondin 2, which seems to make the condition worse. We are developing tiny, slow-release particles made from a special material to deliver a drug called Mianserin directly into the joint. This drug is designed to block the harmful R-spondin 2 signal, aiming to reduce inflammation and joint degeneration.
Who could benefit from this research
Good fit: This research is relevant for individuals living with post-traumatic osteoarthritis, particularly those experiencing joint degeneration.
Not a fit: Patients without post-traumatic osteoarthritis or those with other forms of arthritis may not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this approach could offer a new way to slow down or stop the progression of post-traumatic osteoarthritis by targeting a key disease pathway.
How similar studies have performed: While the drug Mianserin has been identified as an inhibitor, this specific method of sustained delivery using biomaterials to target R-spondin 2 in PTOA is a novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Hankenson, Kurt David — University of Michigan at Ann Arbor
- Study coordinator: Hankenson, Kurt David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.